These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Huannao Yicong decoction ameliorates cognitive deficits in APP/PS1/tau triple transgenic mice by interfering with neurotoxic interaction of Aβ-tau. Zhang H; Chen W; Li Z; Huang Q; Wen J; Chang S; Pei H; Ma L; Li H J Ethnopharmacol; 2024 Jan; 318(Pt B):116985. PubMed ID: 37532075 [TBL] [Abstract][Full Text] [Related]
25. Role of Amyloid-β and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade. Gulisano W; Maugeri D; Baltrons MA; Fà M; Amato A; Palmeri A; D'Adamio L; Grassi C; Devanand DP; Honig LS; Puzzo D; Arancio O J Alzheimers Dis; 2018; 64(s1):S611-S631. PubMed ID: 29865055 [TBL] [Abstract][Full Text] [Related]
26. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice. Xie Y; Tan Y; Zheng Y; Du X; Liu Q J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066 [TBL] [Abstract][Full Text] [Related]
27. Tau in Alzheimer's Disease: Pathological Alterations and an Attractive Therapeutic Target. Gu JL; Liu F Curr Med Sci; 2020 Dec; 40(6):1009-1021. PubMed ID: 33428128 [TBL] [Abstract][Full Text] [Related]
28. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro. Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849 [TBL] [Abstract][Full Text] [Related]
29. CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's Disease. Shentu YP; Huo Y; Feng XL; Gilbert J; Zhang Q; Liuyang ZY; Wang XL; Wang G; Zhou H; Wang XC; Wang JZ; Lu YM; Westermarck J; Man HY; Liu R Cell Rep; 2018 Jul; 24(3):713-723. PubMed ID: 30021167 [TBL] [Abstract][Full Text] [Related]
30. Protein phosphatases and Alzheimer's disease. Braithwaite SP; Stock JB; Lombroso PJ; Nairn AC Prog Mol Biol Transl Sci; 2012; 106():343-79. PubMed ID: 22340724 [TBL] [Abstract][Full Text] [Related]
31. New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease. Zhang F; Zhong RJ; Cheng C; Li S; Le WD Acta Pharmacol Sin; 2021 Sep; 42(9):1382-1389. PubMed ID: 33268824 [TBL] [Abstract][Full Text] [Related]
32. Tau-based therapeutic approaches for Alzheimer's disease - a mini-review. Boutajangout A; Wisniewski T Gerontology; 2014; 60(5):381-5. PubMed ID: 24732638 [TBL] [Abstract][Full Text] [Related]
33. Untangling amyloid-β, tau, and metals in Alzheimer's disease. Savelieff MG; Lee S; Liu Y; Lim MH ACS Chem Biol; 2013 May; 8(5):856-65. PubMed ID: 23506614 [TBL] [Abstract][Full Text] [Related]
34. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease. Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007 [TBL] [Abstract][Full Text] [Related]
35. Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies. Gao Y; Tan L; Yu JT; Tan L Curr Alzheimer Res; 2018; 15(3):283-300. PubMed ID: 28413986 [TBL] [Abstract][Full Text] [Related]
36. Sulforaphene, a CDK5 Inhibitor, attenuates cognitive deficits in a transgenic mouse model of Alzheimer's disease via reducing Aβ Deposition, tau hyperphosphorylation and synaptic dysfunction. Yang W; Xu QQ; Yuan Q; Xian YF; Lin ZX Int Immunopharmacol; 2023 Jan; 114():109504. PubMed ID: 36508924 [TBL] [Abstract][Full Text] [Related]
37. Targeting protein kinases for the treatment of Alzheimer's disease: Recent progress and future perspectives. Li Z; Yin B; Zhang S; Lan Z; Zhang L Eur J Med Chem; 2023 Dec; 261():115817. PubMed ID: 37722288 [TBL] [Abstract][Full Text] [Related]
38. Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease. Reddy PH; Oliver DM Cells; 2019 May; 8(5):. PubMed ID: 31121890 [TBL] [Abstract][Full Text] [Related]
39. The role and therapeutic implication of protein tyrosine phosphatases in Alzheimer's disease. Zhao X; Xiong L; She L; Li L; Huang P; Liang G Biomed Pharmacother; 2022 Jul; 151():113188. PubMed ID: 35676788 [TBL] [Abstract][Full Text] [Related]
40. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM Am J Pathol; 2010 Oct; 177(4):1977-88. PubMed ID: 20802182 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]